Journal of Clinical Oncology publishes pivotal phase 3 data for Jazz Pharmas' Vyxeos®
Jazz Pharmaceuticals announced that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome for injection compared to standard of care cytarabine and daunorubicin (7+3) were published in the Journal of Clinical Oncology. July 19, 2018